



**RESEARCH TOPIC-MEM5
THE ROLE OF HISTOLOGY IN IBD**

Curriculum MEM Clinical

Clinical Unit name and address: IBD center, Department of Gastroenterology, Humanitas Clinical and Research Center-IRCCS

Laboratory name: IBD center, Department of Gastroenterology, Humanitas Clinical and Research Center-IRCCS

Clinical Supervisor: Prof. Silvio Danese, sdanese@hotmail.com

Pre-clinical Supervisor: Prof. Silvio Danese, sdanese@hotmail.com

Abstract

The IBD Center at Humanitas Research Hospital, Rozzano, Milan, Italy, is one of the largest referral Centers for IBD patients in Italy. More than 4,000 patients from all parts of Italy and abroad are currently followed up. The research personnel is currently involved in several national and international research projects and consortia, and has published more than 500 peer-reviewed publications on IBD. We would like to offer a post in our advanced IBD fellowship programme. The main goal of managing IBD patients is to control the inflammatory disease status. Endoscopic mucosal healing is currently the main therapeutic target for these patients. However, many patients with mucosal healing have histological disease activity. The long-term effects of this microscopic inflammation are not known. The relationship between histological activity and patients' outcomes needs to be further investigated.

Main technical approaches

The PhD student will participate in the clinical activity of the IBD center, carrying out outpatient visits and endoscopic procedures and collecting the data necessary for the realization of the project. Furthermore, the PhD student will participate in meetings with other specialists (e.g. pathologists and surgeons) by favoring a multidisciplinary approach and allowing to improve the candidate's personal clinical skills

Scientific references

1. Peyrin-Biroulet L, Bressenot A, Kampman W, et al. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014;12(6):929-34 e2



2. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol.* 2015;110(9):1324-1338. doi:10.1038/ajg.2015.233
3. Ungaro R, Colombel JF, Lisoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. *Am J Gastroenterol.* 2019;114(6):874-883. doi:10.14309/ajg.000000000000183
4. Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. *J Crohns Colitis.* 2020;14(2):254-266. doi:10.1093/ecco-jcc/jjz131
5. Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: should it be considered as a new outcome for ulcerative colitis?. *Expert Opin Biol Ther.* 2020;20(4):407-412. doi:10.1080/14712598.2020.1701652

Type of contract

Place without scholarship.

Posizione senza borsa.